Summary:
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Qualified Participants Must:
18-80 years old male or female
BMI over 25
Diagnosis of Fibrosis